You are here

Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.

Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Porter CK, Welsh M, Riddle MS, Nieh C, Boyko EJ, Gackstetter G, Hooper TI Abstract BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) are two pathotypes of inflammatory bowel disease (IBD) with unique pathology, risk factors and significant morbidity. AIM: To estimate incidence and identify IBD risk factors in a US military population, a healthy subset of the US population, using information…

Read More

The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.

Related Articles The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Lophaven SN, Lynge E, Burisch J Abstract BACKGROUND: Globally, the incidence rates of inflammatory bowel disease (IBD) are increasing; however, data from high-incidence areas are conflicting. Previous studies in Denmark have assessed incidence rates of Crohn’s disease (CD) and ulcerative colitis (UC) using short observation periods. AIM: To investigate trends in IBD incidence in Denmark over a thirty-year period using nationwide data. METHODS: Patients diagnosed with CD or…

Read More

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease.

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 17;: Authors: Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT Abstract BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn’s disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this…

Read More

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply.

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply. Aliment Pharmacol Ther. 2017 Mar;45(6):856-857 Authors: Radford-Smith GL, Hartnell F, Doecke JD PMID: 28211631 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28211631?dopt=Abstract

Read More

Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.

Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 16;: Authors: Law CC, Tariq R, Khanna S, Murthy S, McCurdy JD Abstract BACKGROUND: Clostridium difficile infection (CDI) is associated with increased mortality in inflammatory bowel disease (IBD), but the risk of colectomy is variable and has not been adequately studied. AIM: To perform a systematic review and meta-analysis to assess the impact of CDI on colectomy risk in IBD. METHODS: Multiple databases were…

Read More

Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study.

Related Articles Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study. Aliment Pharmacol Ther. 2017 Feb 06;: Authors: Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M Abstract BACKGROUND: Data on dose de-escalation in patients with Crohn’s disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). METHODS: We selected patients with CD receiving maintenance therapy with ADM 40 mg ETW with…

Read More

Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn’s disease.

Related Articles Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 05;: Authors: Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D’Haens G, Sandborn WJ, Feagan BG Abstract BACKGROUND: Minimising placebo response is essential for drug development. AIM: To conduct a meta-analysis to…

Read More
<< Go Back